Kelly E. Dooley Laboratory

  • Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.

    Research Areas: anti-infective drugs, antiretroviral therapies, tuberculosis and HIV treatments, HIV, lung disease, pharmacology, tuberculosis

    Lab Website

    Principal Investigator

    Kelly Dooley, M.D., M.P.H., Ph.D.

    Department

    Medicine